SX-682

• Description :

  SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity[1].

• CAS Number :

  [1648843-04-2]

• Product Name Alternative :

  (±)-Ibuprofen (L-lysine)

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  CXCR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Inflammation/Immunology; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/sx-682.html

• Purity :

  99.67

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1=CC=C(F)C=C1)C(C=N2)=CN=C2SCC3=CC(OC(F)(F)F)=CC=C3B(O)O

• Molecular Formula :

  C19H14BF4N3O4S

• Molecular Weight :

  467.20

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Sun L, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019 Apr 4;4 (7) .|[2]Lu X, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 30;543 (7647) :728-732.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  CXCR1; CXCR2